Moreover, residual confounding by unmeasured comorbidities (i.e., peripheral neuropathy and microvascular disease) or lifestyle factors (e.g., physical activity, dietary patterns) might influence both sclerostin levels and the risk of PAD. This evidence concerns the gene SOST and peripheral arterial disease.